New cocktail aims to tackle hodgkin lymphoma without prior treatment

NCT ID NCT05922904

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two targeted drugs (brentuximab vedotin and pembrolizumab) plus standard chemotherapy (doxorubicin and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach is safe and effective. Participants have stage II bulky disease or stage III/IV classic Hodgkin lymphoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin, pembrolizumab, doxorubicin, dacarbazine
What this could lead to: If successful, this could offer a more effective first-line treatment for advanced Hodgkin lymphoma, potentially reducing the need for more toxic therapies.
What could go wrong: This is a small, early-phase trial (25 people) focused on safety and response. Results may not apply to all patients, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.